Sai Prasad Desikan

12PUBLICATIONS
41CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMolecular targetsHaematological tumoursAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Oct 07, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.

Jennifer R Brown, Bastien Nguyen, Sai Prasad Desikan

|Apr 16, 2025
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression.

Varsha Gandhi, Shady Tantawy, Burcu Aslan

|Jul 05, 2024
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.

Burcu Aslan, Ganiraju Manyam, Lakesla R Iles

|Feb 01, 2024
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.

Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li

|Jun 10, 2022
Resistance to targeted therapies: delving into FLT3 and IDH.

Sai Prasad Desikan, Naval Daver, Courtney DiNardo

|May 04, 2022
BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient?

Sai Prasad Desikan, Sangeetha Venugopal, Alessandra Ferrajoli

Pageof 2

Frequent Collaborators

3 joint publications

Tapan M Kadia

3 joint publications

Farhad Ravandi

3 joint publications

Varsha Gandhi

2 joint publications

Naval G Daver